Se connecter Inscription gratuite

Interpace Biosciences Inc Propriété institutionnelle

Quel est le Propriété institutionnelle de Interpace Biosciences Inc?

Le Propriété institutionnelle de Interpace Biosciences Inc est 0.00%

Quelle est la définition de Propriété institutionnelle?



La propriété institutionnelle est le montant des actions disponibles d'une société détenues par des fonds mutuels ou des fonds de pension, des compagnies d'assurance, des sociétés d'investissement, des fonds de dotation ou d'autres grandes entités qui gèrent des fonds pour le compte de tiers.

Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.

Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.

Propriété institutionnelle des entreprises dans Health Care secteur sur NASDAQ par rapport à Interpace Biosciences Inc

Que fait Interpace Biosciences Inc?

advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Entreprises avec propriété institutionnelle similaire à Interpace Biosciences Inc